{"transactions":[{"id":4640663,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":85.76,"value":8576.0,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":170000,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640662,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":2451,"price":84.9992,"value":208333.0392,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":169900,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640661,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":2449,"price":84.0707,"value":205889.1443,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":167449,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640660,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":85.76,"value":8576.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":745588,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640659,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":2470,"price":84.9992,"value":209948.024,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":745488,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640658,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":2470,"price":84.0707,"value":207654.629,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":743018,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4627828,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:47:30.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":101.702,"value":305106.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were purchased in multiple transactions at prices ranging from $101.44 to $101.80 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":740548,"source":{"system":"sec-edgar","filing":"0001366074-26-000004","document":"wk-form4_1790632047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000004/wk-form4_1790632047.xml","form_type":"4"}},{"id":4627827,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:47:30.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":98.8803,"value":148320.45,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $98.69 to $99.21 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":737548,"source":{"system":"sec-edgar","filing":"0001366074-26-000004","document":"wk-form4_1790632047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000004/wk-form4_1790632047.xml","form_type":"4"}},{"id":4627826,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:47:30.000Z","date":"2026-09-25","kind":"purchase","planned":false,"acquired":true,"shares":2176,"price":99.5988,"value":216726.9888,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $99.335 to $100.00 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":736048,"source":{"system":"sec-edgar","filing":"0001366074-26-000004","document":"wk-form4_1790632047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000004/wk-form4_1790632047.xml","form_type":"4"}},{"id":4627825,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:47:30.000Z","date":"2026-09-25","kind":"purchase","planned":false,"acquired":true,"shares":3324,"price":98.8659,"value":328630.2516,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $98.27 to $99.26 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":733872,"source":{"system":"sec-edgar","filing":"0001366074-26-000004","document":"wk-form4_1790632047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000004/wk-form4_1790632047.xml","form_type":"4"}},{"id":3513058,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":9681,"price":112.2819,"value":1087001.0739,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares were purchased in multiple transactions at prices ranging from $112.15 to $112.44 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":730548,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513057,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":1219,"price":111.8805,"value":136382.3295,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were purchased in multiple transactions at prices ranging from $111.15 to $112.07 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":720867,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513056,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":108.235,"value":54117.5,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were purchased in multiple transactions at prices ranging from $108.05 to $108.66 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":719648,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513055,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":1100,"price":107.1239,"value":117836.29,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $106.6225 to $107.57 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":719148,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513054,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":6605,"price":100.6388,"value":664719.274,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $100.095 to $100.99 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":718048,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513053,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":5895,"price":99.2948,"value":585342.846,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $98.88 to $99.8316 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":711443,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":1406455,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-16T17:12:34.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":13037,"price":17.13,"value":223323.81,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $16.70 to $17.695, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":705548,"source":{"system":"sec-edgar","filing":"0002007919-24-000049","document":"wk-form4_1726521147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000049/wk-form4_1726521147.xml","form_type":"4"}},{"id":1406454,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-16T17:12:34.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":26963,"price":15.05,"value":405793.15,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":692511,"source":{"system":"sec-edgar","filing":"0002007919-24-000049","document":"wk-form4_1726521147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000049/wk-form4_1726521147.xml","form_type":"4"}},{"id":1410655,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-10T17:00:58.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":8500,"price":15.19,"value":129115.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $15.01 to $15.26, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":665548,"source":{"system":"sec-edgar","filing":"0002007919-24-000045","document":"wk-form4_1726002051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000045/wk-form4_1726002051.xml","form_type":"4"}},{"id":1410654,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-10T17:00:58.000Z","date":"2024-09-09","kind":"purchase","planned":false,"acquired":true,"shares":9500,"price":15.21,"value":144495.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $15.08 to $15.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":657048,"source":{"system":"sec-edgar","filing":"0002007919-24-000045","document":"wk-form4_1726002051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000045/wk-form4_1726002051.xml","form_type":"4"}},{"id":1410653,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-10T17:00:58.000Z","date":"2024-09-06","kind":"purchase","planned":false,"acquired":true,"shares":26000,"price":15.29,"value":397540.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $15.04 to $15.70, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":647548,"source":{"system":"sec-edgar","filing":"0002007919-24-000045","document":"wk-form4_1726002051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000045/wk-form4_1726002051.xml","form_type":"4"}},{"id":1417511,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-03T17:31:03.000Z","date":"2024-09-03","kind":"purchase","planned":false,"acquired":true,"shares":4712,"price":16.31,"value":76852.72,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were purchased in multiple transactions at prices ranging from $16.115 to $16.465, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":165000,"source":{"system":"sec-edgar","filing":"0001739614-24-000037","document":"wk-form4_1725399057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961424000037/wk-form4_1725399057.xml","form_type":"4"}},{"id":1417510,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-03T17:31:03.000Z","date":"2024-09-03","kind":"purchase","planned":false,"acquired":true,"shares":15288,"price":15.66,"value":239410.08,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $15.115 to $16.11, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":160288,"source":{"system":"sec-edgar","filing":"0001739614-24-000037","document":"wk-form4_1725399057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961424000037/wk-form4_1725399057.xml","form_type":"4"}},{"id":1417509,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-03T17:31:03.000Z","date":"2024-08-30","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":14.02,"value":140200.0,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $13.96 to $14.13, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":145000,"source":{"system":"sec-edgar","filing":"0001739614-24-000037","document":"wk-form4_1725399057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961424000037/wk-form4_1725399057.xml","form_type":"4"}},{"id":1417508,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-03T17:31:03.000Z","date":"2024-08-29","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":14.03,"value":140300.0,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $13.9079 to $14.245, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":135000,"source":{"system":"sec-edgar","filing":"0001739614-24-000037","document":"wk-form4_1725399057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961424000037/wk-form4_1725399057.xml","form_type":"4"}},{"id":1425080,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-22T16:29:47.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":12945,"price":12.93,"value":167378.85,"ownership":{"direct":false,"nature":"The Mark Paul Lappe Roth IRA"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were purchased in multiple transactions at prices ranging from $12.82 to $13.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":54865,"source":{"system":"sec-edgar","filing":"0002007919-24-000038","document":"wk-form4_1724358581.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000038/wk-form4_1724358581.xml","form_type":"4"}},{"id":1425079,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-22T16:29:47.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":27055,"price":12.97,"value":350903.35,"ownership":{"direct":false,"nature":"The Mark Paul Lappe Roth IRA"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $12.77 to $13.14, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":41920,"source":{"system":"sec-edgar","filing":"0002007919-24-000038","document":"wk-form4_1724358581.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000038/wk-form4_1724358581.xml","form_type":"4"}},{"id":1497590,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T18:22:58.000Z","date":"2024-05-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":145000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the Agreement and Plan of Merger, dated January 22, 2024 (the \"Merger Agreement\"), by and among Inhibrx, Inc. (the \"Issuer\"), Aventis Inc., a Pennsylvania corporation (\"Parent\") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation (\"Merger Sub\") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This stock option was canceled in the Merger and converted into the right to receive the contingent payment described in the following sentence. If the Milestone is achieved, the cash amount to be paid in respect of each such stock option will be equal to (x) $35.00 (representing the sum of the Closing Amount of $30.00 and the Milestone Payment of $5.00) minus (y) the option exercise price per share, subject to applicable tax withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments thirty-six (36) months thereafter."}],"balance_after":0,"derivative":{"exercise_price":33.63,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0000950142-24-001500","document":"es240484812_4-lappe.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001500/es240484812_4-lappe.xml","form_type":"4"}},{"id":1497589,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T18:22:58.000Z","date":"2024-05-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the Agreement and Plan of Merger, dated January 22, 2024 (the \"Merger Agreement\"), by and among Inhibrx, Inc. (the \"Issuer\"), Aventis Inc., a Pennsylvania corporation (\"Parent\") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation (\"Merger Sub\") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer's common stock under such stock option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter."}],"balance_after":0,"derivative":{"exercise_price":23.3,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950142-24-001500","document":"es240484812_4-lappe.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001500/es240484812_4-lappe.xml","form_type":"4"}},{"id":1497588,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:22:58.000Z","date":"2024-05-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":59462,"price":30,"value":1783860.0,"ownership":{"direct":false,"nature":"The Mark Paul Lappe Roth IRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the Agreement and Plan of Merger, dated January 22, 2024 (the \"Merger Agreement\"), by and among Inhibrx, Inc. (the \"Issuer\"), Aventis Inc., a Pennsylvania corporation (\"Parent\") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation (\"Merger Sub\") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the \"Closing Amount\"), plus (ii) one (1) contractual contingent value right (\"CVR\") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the \"Milestone Payment\"), upon the achievement of certain regulatory milestones (\"Milestone\") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001500","document":"es240484812_4-lappe.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001500/es240484812_4-lappe.xml","form_type":"4"}},{"id":1497587,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:22:58.000Z","date":"2024-05-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"price":30,"value":15000000.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the Agreement and Plan of Merger, dated January 22, 2024 (the \"Merger Agreement\"), by and among Inhibrx, Inc. (the \"Issuer\"), Aventis Inc., a Pennsylvania corporation (\"Parent\") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation (\"Merger Sub\") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the \"Closing Amount\"), plus (ii) one (1) contractual contingent value right (\"CVR\") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the \"Milestone Payment\"), upon the achievement of certain regulatory milestones (\"Milestone\") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities were directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001500","document":"es240484812_4-lappe.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001500/es240484812_4-lappe.xml","form_type":"4"}},{"id":1497586,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:22:58.000Z","date":"2024-05-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2486192,"price":30,"value":74585760.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the Agreement and Plan of Merger, dated January 22, 2024 (the \"Merger Agreement\"), by and among Inhibrx, Inc. (the \"Issuer\"), Aventis Inc., a Pennsylvania corporation (\"Parent\") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation (\"Merger Sub\") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the \"Closing Amount\"), plus (ii) one (1) contractual contingent value right (\"CVR\") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the \"Milestone Payment\"), upon the achievement of certain regulatory milestones (\"Milestone\") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities were directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001500","document":"es240484812_4-lappe.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001500/es240484812_4-lappe.xml","form_type":"4"}},{"id":1497585,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T18:10:50.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F4","text":"This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter."}],"balance_after":300000,"derivative":{"exercise_price":15.86,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000950142-24-001493","document":"es240484863_4-lappe.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001493/es240484863_4-lappe.xml","form_type":"4"}},{"id":1497584,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:10:50.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":14865,"ownership":{"direct":false,"nature":"The Mark Paul Lappe Roth IRA"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."}],"balance_after":14865,"source":{"system":"sec-edgar","filing":"0000950142-24-001493","document":"es240484863_4-lappe.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001493/es240484863_4-lappe.xml","form_type":"4"}},{"id":1497583,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:10:50.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":125000,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0000950142-24-001493","document":"es240484863_4-lappe.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001493/es240484863_4-lappe.xml","form_type":"4"}},{"id":1497582,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:10:50.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":621548,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":621548,"source":{"system":"sec-edgar","filing":"0000950142-24-001493","document":"es240484863_4-lappe.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001493/es240484863_4-lappe.xml","form_type":"4"}},{"id":1983164,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2023-03-01T16:41:37.000Z","date":"2023-02-28","kind":"sale","acquired":false,"shares":60,"price":25.0208,"value":1501.248,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $25.005 to $25.07, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2486192,"source":{"system":"sec-edgar","filing":"0001739614-23-000014","document":"wf-form4_167770687699240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961423000014/wf-form4_167770687699240.xml","form_type":"4"}},{"id":2047305,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2023-01-24T18:46:02.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":63,"price":26.1127,"value":1645.1001,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $26.105 to $26.13, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2486252,"source":{"system":"sec-edgar","filing":"0001739614-23-000010","document":"wf-form4_167460394406722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961423000010/wf-form4_167460394406722.xml","form_type":"4"}},{"id":2047304,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2023-01-24T18:46:02.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":4272,"price":25.71,"value":109833.12,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $25.105 to $26.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2486315,"source":{"system":"sec-edgar","filing":"0001739614-23-000010","document":"wf-form4_167460394406722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961423000010/wf-form4_167460394406722.xml","form_type":"4"}},{"id":2047303,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2023-01-24T18:46:02.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":21665,"price":25.3572,"value":549363.738,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $25.00 to $25.61, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2490587,"source":{"system":"sec-edgar","filing":"0001739614-23-000010","document":"wf-form4_167460394406722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961423000010/wf-form4_167460394406722.xml","form_type":"4"}},{"id":2072209,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-03T18:11:52.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments forthirty-six (36) months thereafter."}],"balance_after":100000,"derivative":{"exercise_price":23.3,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001739614-23-000004","document":"wf-form4_167278749618241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961423000004/wf-form4_167278749618241.xml","form_type":"4"}},{"id":2079522,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-12-20T16:59:55.000Z","date":"2022-12-19","kind":"sale","acquired":false,"shares":754,"price":26.2859,"value":19819.5686,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $26.00 to $26.86, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2512252,"source":{"system":"sec-edgar","filing":"0001739614-22-000130","document":"wf-form4_167157357332535.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000130/wf-form4_167157357332535.xml","form_type":"4"}},{"id":2079521,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-12-20T16:59:55.000Z","date":"2022-12-19","kind":"sale","acquired":false,"shares":25246,"price":25.5337,"value":644623.7902,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $25.00 to $25.99, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2513006,"source":{"system":"sec-edgar","filing":"0001739614-22-000130","document":"wf-form4_167157357332535.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000130/wf-form4_167157357332535.xml","form_type":"4"}},{"id":2110072,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-11-18T17:06:37.000Z","date":"2022-11-17","kind":"sale","acquired":false,"shares":1150,"price":32.3837,"value":37241.255,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The shares were sold in multiple transactions at prices ranging from $31.97 to $32.75, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2538252,"source":{"system":"sec-edgar","filing":"0001739614-22-000124","document":"wf-form4_166880918186617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000124/wf-form4_166880918186617.xml","form_type":"4"}},{"id":2110071,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-11-18T17:06:37.000Z","date":"2022-11-17","kind":"sale","acquired":false,"shares":912,"price":30.668,"value":27969.216,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The shares were sold in multiple transactions at prices ranging from $30.52 to $30.68, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2539402,"source":{"system":"sec-edgar","filing":"0001739614-22-000124","document":"wf-form4_166880918186617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000124/wf-form4_166880918186617.xml","form_type":"4"}},{"id":2110070,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-11-18T17:06:37.000Z","date":"2022-11-17","kind":"sale","acquired":false,"shares":6773,"price":30.1485,"value":204195.7905,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares were sold in multiple transactions at prices ranging from $29.47 to $30.31, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2540314,"source":{"system":"sec-edgar","filing":"0001739614-22-000124","document":"wf-form4_166880918186617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000124/wf-form4_166880918186617.xml","form_type":"4"}},{"id":2110069,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-11-18T17:06:37.000Z","date":"2022-11-17","kind":"sale","acquired":false,"shares":1767,"price":28.8574,"value":50991.0258,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $28.47 to $29.40, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2547087,"source":{"system":"sec-edgar","filing":"0001739614-22-000124","document":"wf-form4_166880918186617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000124/wf-form4_166880918186617.xml","form_type":"4"}},{"id":2110068,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-11-18T17:06:37.000Z","date":"2022-11-17","kind":"sale","acquired":false,"shares":4333,"price":27.4492,"value":118937.3836,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $27.04 to $28.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2548854,"source":{"system":"sec-edgar","filing":"0001739614-22-000124","document":"wf-form4_166880918186617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000124/wf-form4_166880918186617.xml","form_type":"4"}},{"id":2110067,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-11-18T17:06:37.000Z","date":"2022-11-17","kind":"sale","acquired":false,"shares":4106,"price":26.5703,"value":109097.6518,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $26.01 to $26.96, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2553187,"source":{"system":"sec-edgar","filing":"0001739614-22-000124","document":"wf-form4_166880918186617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000124/wf-form4_166880918186617.xml","form_type":"4"}},{"id":2110066,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-11-18T17:06:37.000Z","date":"2022-11-17","kind":"sale","acquired":false,"shares":6959,"price":25.3596,"value":176477.4564,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $25.00 to $25.985, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2557293,"source":{"system":"sec-edgar","filing":"0001739614-22-000124","document":"wf-form4_166880918186617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000124/wf-form4_166880918186617.xml","form_type":"4"}},{"id":2135359,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-10-18T16:37:13.000Z","date":"2022-10-17","kind":"sale","acquired":false,"shares":121,"price":31.5071,"value":3812.3591,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $31.48 to $31.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2564252,"source":{"system":"sec-edgar","filing":"0001739614-22-000107","document":"wf-form4_166612539476406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000107/wf-form4_166612539476406.xml","form_type":"4"}},{"id":2135358,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-10-18T16:37:13.000Z","date":"2022-10-17","kind":"sale","acquired":false,"shares":2892,"price":30.8055,"value":89089.506,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $30.48 to $31.44, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2564373,"source":{"system":"sec-edgar","filing":"0001739614-22-000107","document":"wf-form4_166612539476406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000107/wf-form4_166612539476406.xml","form_type":"4"}},{"id":2135357,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-10-18T16:37:13.000Z","date":"2022-10-17","kind":"sale","acquired":false,"shares":14006,"price":29.9245,"value":419122.547,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $29.475 to $30.47, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2567265,"source":{"system":"sec-edgar","filing":"0001739614-22-000107","document":"wf-form4_166612539476406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000107/wf-form4_166612539476406.xml","form_type":"4"}},{"id":2135356,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2022-10-18T16:37:13.000Z","date":"2022-10-17","kind":"sale","acquired":false,"shares":8981,"price":28.6626,"value":257418.8106,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $28.475 to $29.47, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2581271,"source":{"system":"sec-edgar","filing":"0001739614-22-000107","document":"wf-form4_166612539476406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961422000107/wf-form4_166612539476406.xml","form_type":"4"}},{"id":2904009,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-19T16:10:59.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(3) Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter."}],"balance_after":145000,"derivative":{"exercise_price":33.63,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001739614-21-000018","document":"wf-form4_161109064662411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961421000018/wf-form4_161109064662411.xml","form_type":"4"}},{"id":2904008,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2021-01-19T16:10:59.000Z","date":"2020-12-28","kind":"gift","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) This transaction involved a gift of securities by the Lappe Family Trust to a trust for the benefit of the reporting person's immediate family."}],"balance_after":500000,"source":{"system":"sec-edgar","filing":"0001739614-21-000018","document":"wf-form4_161109064662411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961421000018/wf-form4_161109064662411.xml","form_type":"4"}},{"id":2904007,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":116228,"kind":"organization","name":"Lappe Family Trust","position":2,"cik":"0001821266","reported_name":"Lappe Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"To be Verified"}}],"security":"Common Stock","published_at":"2021-01-19T16:10:59.000Z","date":"2020-12-28","kind":"gift","acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) This transaction involved a gift of securities by the Lappe Family Trust to a trust for the benefit of the reporting person's immediate family."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(2) These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is the trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":2590252,"source":{"system":"sec-edgar","filing":"0001739614-21-000018","document":"wf-form4_161109064662411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961421000018/wf-form4_161109064662411.xml","form_type":"4"}}]}